Affinity Capital Advisors LLC Cuts Stock Position in Eli Lilly and Company $LLY

Key Points

• Affinity Capital Advisors LLC has reduced its stock position in Eli Lilly and Company by 10.7%, holding 4,849 shares worth approximately $3.78 million after selling 584 shares in the second quarter.
• Several other institutional investors have increased their stakes, with GSG Advisors LLC raising its holdings by 8.0% during the same period, indicating a mixed outlook among institutional investors.
• Eli Lilly recently reported quarterly earnings of $6.31 EPS, surpassing estimates significantly, with revenue of $15.56 billion, showcasing a 37.6% year-over-year increase.

Affinity Capital Advisors LLC cut its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,849 shares of the company's stock after selling 584 shares during the quarter. Eli Lilly and Company accounts for 0.7% of Affinity Capital Advisors LLC's investment portfolio, making the stock its 28th largest position. Affinity Capital Advisors LLC's holdings in Eli Lilly and Company were worth $3,780,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. GSG Advisors LLC boosted its stake in shares of Eli Lilly and Company by 8.0% in the second quarter. GSG Advisors LLC now owns 448 shares of the company's stock worth $349,000 after acquiring an additional 33 shares during the last quarter. Mirador Capital Partners LP boosted its stake in shares of Eli Lilly and Company by 2.6% in the second quarter. Mirador Capital Partners LP now owns 1,413 shares of the company's stock worth $1,101,000 after acquiring an additional 36 shares during the last quarter. Baron Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 2.4% in the second quarter. Baron Wealth Management LLC now owns 642 shares of the company's stock worth $501,000 after acquiring an additional 15 shares during the last quarter. Goelzer Investment Management Inc. boosted its stake in shares of Eli Lilly and Company by 1.3% in the second quarter. Goelzer Investment Management Inc. now owns 557,659 shares of the company's stock worth $434,712,000 after acquiring an additional 7,349 shares during the last quarter. Finally, Lifelong Wealth Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 5.3% in the second quarter. Lifelong Wealth Advisors Inc. now owns 1,169 shares of the company's stock worth $911,000 after acquiring an additional 59 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LLY. Cantor Fitzgerald lowered their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research note on Sunday, August 17th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price target for the stock from $675.00 to $700.00 in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Finally, Guggenheim lowered their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $947.39.

Insider Activity

In related news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 2.1%

LLY opened at $763.59 on Wednesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.86. The stock has a market capitalization of $722.71 billion, a price-to-earnings ratio of 49.91, a PEG ratio of 1.04 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business has a fifty day moving average price of $740.25 and a 200 day moving average price of $774.23.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.